Free Newsletter
Glaxo ready to wait for late-stage Cervarix data
GlaxoSmithKline now says it will wait for the completion of a late-stage trial of its cervical cancer vaccine Cervarix before answering the FDA's questions about the therapy. That will push back any approval of Cervarix until 2010, at the earliest. And it confirms some of the worst fears of market analysts, who see Merck's Gardasil gobbling up the market long before Cervarix arrives on the scene.
The long-term efficacy trial that GSK is waiting on tracks the real-world experiences of girls and young women who have been vaccinated. The cancer vaccine is on sale in 67 countries.
- read the report in the Financial Times
Related Articles:
Glaxo's Cervarix delayed until late 2009
GSK hit with Cervarix application delay
U.K. health officials in cancer vaccine fight
France picks Gardasil over GSK upstart
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
More Research Reports >>
SHARE
WITH: